Form 4: SOPHIA GENETICS SA: Insider Sells Shares

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, reported a sale of 5,000 ordinary shares.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 ordinary shares on May 26, 2026.
• The sale was executed as part of a pre-arranged trading plan under Rule 10b5-1(c).
• The shares were sold at a weighted average price of $4.9548, with individual transactions ranging from $4.78 to $5.01.
• Following the transaction, Mr. Menu beneficially owns 250,780 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was conducted under a pre-arranged trading plan, mitigating concerns of opportunistic insider trading, but any insider sale warrants attention.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-arranged trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors. While this transaction was made under a Rule 10b5-1 plan, which is designed to avoid insider trading concerns, the sale by a key executive like the Chief Medical Officer may still attract attention.

Stakeholder Impact

• Shareholders: May observe the sale as a signal, though the 10b5-1 plan mitigates negative interpretation.
• Management: Demonstrates adherence to pre-planned trading strategies.

Key Dates

Keywords

SOPHiA GENETICS SA, Insider Trading, Form 4, Share Sale, Rule 10b5-1, Chief Medical Officer, Philippe Menu